Stockreport

Novo is suing Hims & Hers to halt obesity drug copycats [Los Angeles Times (CA)]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Hims is breaching the US patent on semaglutide, the active ingredient in Novo's blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims [Read more]